Label

How We Work

Grant

Back

Print

PATH


January 2017
To transfer technology and to develop the manufacturing processes for the P2-VP8 trivalent non-replicating rotavirus vaccine at SK Chemicals, Seoul, South Korea; a potential vaccine against severe rotavirus disease in infants
$9,496,938
54
Enteric and Diarrheal Diseases
Global Health
Seattle, Washington
http://www.path.org

Visit Our Blog